Skip to main content
Homepage
PARTIAL Analysis Report
Sep 4, 2026
58 days ago · 4% complete
Partial analysis — no complete end-to-end run on record.
No report run on this ticker yet Only preliminary foundational data below
NOT YET RESEARCHED No report has been run on TNDM yet. What you are seeing is foundational data only — price, profile and filings — not the full analysis (lenses, memo, scores and the AI panel arrive with the first report).
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for Tandem Diabetes Care, Inc. (TNDM) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysis — the core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at voiceoftrades.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

Tandem Diabetes Care, Inc.

TNDM NASDAQ
Healthcare · Medical Devices
San Diego, CA 92130, United States tandemdiabetes.com Updated Nov 1, 8:18pm
Price
$20.12
Market Cap
$1.4B
Employees
2,500
Beta
1.54
Avg Volume
1,930,296
CEO
Mr. John F. Sheridan

Tandem Diabetes Care, Inc. is a medical device company focused on diabetes management technology. Tandem Diabetes Care develops and commercializes automated insulin delivery systems designed for people living with insulin-dependent diabetes, with its current product portfolio centered on the t:slim X2 insulin pump and the Tandem Mobi insulin pump. The company’s systems integrate Control-IQ technology and work with compatible continuous glucose monitors to help automate insulin delivery and support day-to-day glucose management. Tandem Diabetes Care also provides related products and services such as infusion sets, cartridges, software updates, data management tools, and mobile applications that support pump users and healthcare providers. Its offerings are used in the United States and in international markets, positioning the company as a specialized player in the broader diabetes care and medical technology sector.

Runs with full report
Price Overview
Current data · timestamped when a report runs
$16.28
Change
-0.53 (-3.18%)
Day Range
$16.25 – $17.01
52-Week Range
$11.46 – $29.65
50-Day MA
$19.42
200-Day MA
$19.71
Volume
151,805.00
0Company Classification 1Industry Landscape 2Company Momentum 3Forward Projection 4aDCF Valuation 4bEarnings Power Value 4cAnchored PE 4dReverse DCF 4eRevenue-Based DCF 4fAnchored P/S 4gScenario Analysis 4hDividend Discount Model 4iBook Value Analysis 4jInsider Activity 4fCash Flow Quality 4gDebt Maturity Risk 4hMacro Environment 4iSector Intelligence 4jRevenue Confidence 4kSensitivity Analysis 4lSector Demand Cycle 5AI Investigation 5bThesis Evaluation 6Valuation Synthesis
computed not applicable not yet run 1 computed · 7 not applicable · 16 not yet run
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for TNDM — it's generated by the pipeline (market-narrative step).
Claude Reading
Claude Opus reviews the pipeline's raw data + every prior verdict, then writes an independent take.
No AI findings yet for TNDM — they're generated by the pipeline (ai-findings step) when a report is run on this ticker.
GPT Reading
GPT reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No GPT reading yet for TNDM — it's generated by the pipeline (gpt-critique step) after the other Big-3 seats, when a report is run on this ticker.
Grok Reading
Grok (xAI) reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No Grok reading yet for TNDM — it's generated by the pipeline (grok-critique step) alongside the other Big-3 seats, when a report is run on this ticker.
Advanced Analysis Forensic deep-dive · separate lenses
A separate, manually-run forensic pipeline (dilution, earnings quality, liquidity → two scored lenses → the play). Hasn't been run for this ticker yet.
Community AI Feedback
No community reviews yet for TNDM. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this